Cargando…
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
BACKGROUND: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD). OBJECTIVE: Because it is believed that type...
Autores principales: | Ungar, Benjamin, Glickman, Jacob W., Golant, Alexandra K., Dubin, Celina, Marushchak, Olga, Gontzes, Alyssa, Mikhaylov, Daniela, Singer, Giselle K., Baum, Danielle, Wei, Nancy, Sanin, Antonio, Gruenstein, Diana, Lebwohl, Mark G., Pavel, Ana B., Guttman-Yassky, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558098/ https://www.ncbi.nlm.nih.gov/pubmed/34737108 http://dx.doi.org/10.1016/j.jaip.2021.10.050 |
Ejemplares similares
-
The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
por: Ungar, Benjamin, et al.
Publicado: (2022) -
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021) -
Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab
por: Gruenstein, Diana, et al.
Publicado: (2020)